What you need to keep in mind is that the priorities of the clinical academics differ from those of the company and investors. For the academics it’s essential to present at the top congresses and to publish in the top peer-review journals. They cannot do that if companies have already disclosed  too much information through press releases. Companies have no choice but to cooperate or they will not get the support and participation of the best clinical investigators in future trials. Frustrating for investors, but it’s the way it works.

Dr Wong is very familiar with all this, of course, because he is a clinical academic himself (endocrinology).

Not so long ago, TLD were never first publicised through press releases. They were only ever presented first in congresses. The press conferences came later.